Medicine and Dentistry
Patient
100%
Classical Hodgkin Lymphoma
57%
Therapeutic Procedure
56%
Child
45%
Diseases
43%
Pediatrics
33%
Vincristine
31%
Radiation Therapy
28%
Event Free Survival
25%
Adult
24%
Group Therapy
24%
B Cell
23%
Prednisone
22%
Leukemia
20%
Combination Therapy
20%
Incidence
19%
Waldeyer Ring
19%
Acute B-Cell Lymphoblastic Leukemia
19%
Langerhans Cell Histiocytosis
19%
Rituximab
19%
Ifosfamide
18%
Carboplatin
18%
Etoposide
17%
Adolescent
17%
Non-Hodgkin Lymphoma
16%
Marker
15%
Procarbazine
15%
Mortality
15%
Inpatient
15%
Diagnosis
15%
Survival
14%
Lymphoma
14%
Cyclophosphamide
14%
Burkitt's Lymphoma
13%
Precursor
13%
Spontaneous Remission
13%
Pediatrics Patient
13%
Overall Survival
12%
Chemotherapy
11%
Survival Rate
11%
Childhood
11%
Cancer
11%
Lymphoblastic Lymphoma
11%
Cells
10%
Biological Marker
10%
Hodgkin's Lymphoma
10%
Antibody
9%
Acute Myeloid Leukemia
9%
Targeted Therapy
9%
Pediatric Cancer
9%
Biochemistry, Genetics and Molecular Biology
Childhood
23%
Positron Emission Tomography-Computed Tomography
21%
Whole-Body Magnetic Resonance Imaging
20%
Magnetic Resonance Imaging
20%
Langerhans Cell
19%
Prednisone
16%
Procarbazine
15%
Mutation
15%
Cyclophosphamide
14%
Event Free Survival
13%
Clinical Trial
9%
Motivation
9%
Staging
9%
Association
8%
Pediatrics
8%
Prevalence
6%
Reading
5%
Pharmacology, Toxicology and Pharmaceutical Science
Thymus and Activation Regulated Chemokine
19%
Leukemia
19%
Prednisone
16%
Vincristine
16%
Procarbazine
15%
Diseases
15%
Lymphoma
14%
Cyclophosphamide
14%
Classical Hodgkin Lymphoma
13%
Acute Myeloid Leukemia
9%
Antibody
9%
Drug Development
9%
Event Free Survival
9%